{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T17:00:40Z","timestamp":1780246840201,"version":"3.54.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbrc.2026.153908","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:45:45Z","timestamp":1779291945000},"page":"153908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ARID1A loss drives osimertinib resistance by epigenetically suppressing PTEN and activating the Akt pathway in lung cancer"],"prefix":"10.1016","volume":"825","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-9192","authenticated-orcid":false,"given":"Xue","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153908_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2025.101206","article-title":"Replication stress response and radioresistance in lung cancer: mechanistic insights and advanced therapeutic approaches","volume":"56","author":"Kundu","year":"2025","journal-title":"Curr. Probl. Cancer"},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib2","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.bbrc.2026.153908_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-094632","article-title":"Efficacy and safety of iodine-125 seed implantations combined with chemotherapy and immunotherapy for patients with non-small cell lung cancer: protocol for a systematic review and meta-analysis","volume":"15","author":"Wu","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.bbrc.2026.153908_bib4","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou","year":"2024","journal-title":"Lancet Reg. Health West. Pac."},{"issue":"5","key":"10.1016\/j.bbrc.2026.153908_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/0008-5472.CAN-24-1611","article-title":"Targeting arachidonic acid metabolism enhances immunotherapy efficacy in ARID1A-Deficient colorectal cancer","volume":"85","author":"Cui","year":"2025","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bbrc.2026.153908_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.molmed.2023.04.005","article-title":"ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications","volume":"29","author":"Jin","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbrc.2026.153908_bib7","article-title":"PTEN-mediated resistance in cancer: from foundation to future therapies","volume":"14","author":"Tufail","year":"2025","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.bbrc.2026.153908_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3389\/fonc.2020.01569","article-title":"Role of ubiquitination in PTEN cellular homeostasis and its implications in GB drug resistance","volume":"10","author":"Xia","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2026.153908_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.gmg.2025.100051","article-title":"Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation","volume":"12","author":"Liu","year":"2025","journal-title":"Glob Med Genet"},{"key":"10.1016\/j.bbrc.2026.153908_bib10","article-title":"New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era","volume":"44","author":"Rubio-Perez","year":"2025","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"suppl_1","key":"10.1016\/j.bbrc.2026.153908_bib12","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.bbrc.2026.153908_bib13","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","article-title":"Tackling osimertinib resistance in EGFR-Mutant non-small cell lung cancer","volume":"29","author":"Blaquier","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.153908_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2026.153908_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102287","article-title":"Targeting ARID1A mutations in cancer","volume":"100","author":"Mullen","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10020-022-00469-6","article-title":"Roles of ARID1A variations in colorectal cancer: a collaborative review","volume":"28","author":"Zhao","year":"2022","journal-title":"Mol. Med."},{"issue":"9","key":"10.1016\/j.bbrc.2026.153908_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/cac2.12465","article-title":"Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbrc.2026.153908_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2018.04.013","article-title":"ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2","volume":"427","author":"Luo","year":"2018","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.bbrc.2026.153908_bib19","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s43032-024-01585-w","article-title":"ARID1A in gynecologic precancers and cancers","volume":"31","author":"Morgan","year":"2024","journal-title":"Reprod. Sci."},{"issue":"7","key":"10.1016\/j.bbrc.2026.153908_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.31083\/ph.2022.1881","article-title":"ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2","volume":"77","author":"Li","year":"2022","journal-title":"Pharmazie"},{"issue":"5","key":"10.1016\/j.bbrc.2026.153908_bib21","first-page":"1683","article-title":"Role of ARID1A in epithelial-mesenchymal transition in breast cancer and its effect on cell sensitivity to 5-FU","volume":"46","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2026.153908_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11596-023-2731-8","article-title":"ARID1A inactivation increases expression of circ0008399 and promotes cisplatin resistance in bladder cancer","volume":"43","author":"Jiang","year":"2023","journal-title":"Curr Med Sci"},{"issue":"7","key":"10.1016\/j.bbrc.2026.153908_bib23","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/modpathol.2013.216","article-title":"Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma","volume":"27","author":"Huang","year":"2014","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib24","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1038\/s41467-022-34871-9","article-title":"ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12935-023-03154-8","article-title":"The effects of ARID1A mutation in gastric cancer and its significance for treatment","volume":"23","author":"Lu","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-024-00594-4","article-title":"A cohort-based multi-omics identifies nuclear translocation of eIF5B\/PD-L1\/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma","volume":"14","author":"Sun","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.bbrc.2026.153908_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12916-024-03389-w","article-title":"Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer","volume":"22","author":"Han","year":"2024","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib29","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/CAD.0000000000001242","article-title":"A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance","volume":"33","author":"Qu","year":"2022","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib30","doi-asserted-by":"crossref","first-page":"8402","DOI":"10.1038\/s41467-025-63465-4","article-title":"Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer","volume":"16","author":"Hartner","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.153908_bib31","article-title":"Discovery of paradoxical genes: reevaluating the prognostic impact of overexpressed genes in cancer","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153908_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2116844","article-title":"IRE1\u03b1 overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response","volume":"11","author":"Martinez-Turtos","year":"2022","journal-title":"Oncoimmunology"},{"issue":"10454","key":"10.1016\/j.bbrc.2026.153908_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bbrc.2026.153908_bib34","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/jcmm.12363","article-title":"A novel functional interplay between progesterone Receptor-B and PTEN, via AKT, modulates autophagy in breast cancer cells","volume":"18","author":"De Amicis","year":"2014","journal-title":"J. Cell Mol. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T16:08:59Z","timestamp":1780243739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26006728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["S0006291X26006728"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153908","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ARID1A loss drives osimertinib resistance by epigenetically suppressing PTEN and activating the Akt pathway in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153908"}}